{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:11:38Z","timestamp":1790518298610,"version":"4.1.0"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Voriconazole (VCZ) exhibits great inter- and intrapatient variability. The latter variation cannot exclusively be explained by concomitant medications, liver disease or dysfunction, and genetic polymorphisms in cytochrome P450 2C19 (CYP2C19). We hypothesized that inflammatory response in patients under VCZ medication might also influence this fluctuation in concentrations. In this study, we explored the association between inflammation, reflected by the C-reactive protein (CRP) concentration, and VCZ trough concentrations over time. A retrospective analysis of data was performed for patients with more than one steady-state VCZ trough concentration and a CRP concentration measured on the same day. A longitudinal analysis was used for series of observations obtained from many study participants over time. The approach involved inclusion of random effects and autocorrelation in linear models to reflect within-person cross-time correlation. A total of 50 patients were eligible for the study, resulting in 139 observations (paired VCZ and CRP concentrations) for the analysis, ranging from 2 to 6 observations per study participant. Inflammation, marked by the CRP concentration, had a significant association with VCZ trough concentrations (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). Covariates such as age and interacting comedication ([es]omeprazole), also showed a significant correlation between VCZ and CRP concentrations (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). The intrapatient variation of trough concentrations of VCZ was 1.401 (confidence interval [CI], 0.881 to 2.567), and the interpatient variation was 1.756 (CI, 0.934 to 4.440). The autocorrelation between VCZ trough concentrations at two sequential time points was calculated at 0.71 (CI, 0.51 to 0.92). The inflammatory response appears to play a significant role in the largely unpredictable pharmacokinetics of VCZ, especially in patients with high inflammatory response, as reflected by high CRP concentrations.\n          <\/jats:p>","DOI":"10.1128\/aac.02830-15","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T03:49:32Z","timestamp":1455680972000},"page":"2727-2731","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":64,"title":["Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations"],"prefix":"10.1128","volume":"60","author":[{"given":"M. A.","family":"Encalada Ventura","sequence":"first","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J. P.","family":"van Wanrooy","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F. R.","family":"Span","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Hematology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G. G.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Surgical Intensive Care, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. R.","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Eindhoven University of Technology, Department of Mathematics and Computer Science, Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. R. A.","family":"Uges","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"van der Werf","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Departments of Internal Medicine and Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G. W.","family":"Kosterink","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"},{"name":"University of Groningen, Department of Pharmacy, Section Pharmacotherapy and Pharmaceutical Care, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. C.","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.003"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-105"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645070-00002"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2010.503814"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2333-z"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008327537"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01316-08"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp416"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(01)00165-6"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.1.4.629"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01034-9"},{"key":"e_1_3_1_15_2","first-page":"602","article-title":"Drug disease interactions: role of inflammatory mediators in disease and variability in drug response","volume":"8","author":"Kulmatycki KM","year":"2005","unstructured":"Kulmatycki KM, Jamali F. 2005. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci 8:602\u2013625.","journal-title":"J Pharm Pharm Sci"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03820-14"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04789-14"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1046\/j.1365-2125.2003.01992.x","article-title":"The pharmacokinetics and safety of intravenous voriconazole\u2014a novel wide-spectrum antifungal agent","volume":"56","author":"Purkins L","year":"2003","unstructured":"Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. 2003. The pharmacokinetics and safety of intravenous voriconazole\u2014a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 56(Suppl 1):S2\u2013S9.","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01993.x"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2546-2553.2002"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.11.017"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku242"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018747"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.46.120604.141059"},{"key":"e_1_3_1_25_2","first-page":"207","article-title":"Regulation of cytochrome P450 by inflammatory mediators: why and how?","volume":"29","author":"Morgan ET","year":"2001","unstructured":"Morgan ET. 2001. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 29:207\u2013212.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.061093"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-08"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.731"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1566"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03534.x"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903485637"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0310057X0903700217","article-title":"An update on C-reactive protein for intensivists","volume":"37","author":"Ho KM","year":"2009","unstructured":"Ho KM, Lipman J. 2009. An update on C-reactive protein for intensivists. Anaesth Intensive Care 37:234\u2013241.","journal-title":"Anaesth Intensive Care"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R400025200"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02830-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02830-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:45:29Z","timestamp":1645476329000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02830-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1128\/AAC.02830-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02830-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"2015-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}